France Bans Nicotine Pouches: What It Means for Suppliers

On April 1, 2026, France's ban on nicotine pouch sales took effect under Décret n° 2025-898 of September 5, 2025. The decree prohibits the production, manufacture, transport, import, export, possession, offer, transfer, acquisition and use of oral products containing nicotine, in the form of portion pouches, porous pouches, paste, beads, liquids, chewing gum, lozenges, strips or any combination of those forms. Only medicines, medical devices, pharmaceutical raw materials, chewing tobacco and foodstuffs that naturally contain nicotine are carved out.

The mechanism matters, because it explains the penalties. France did not legislate a bespoke pouch statute. It classified oral consumer nicotine under the poisonous substances regime of the Public Health Code, which means breaches fall under Article L5432-1 CSP: five years' imprisonment and a fine of EUR 375,000, rising to seven years and EUR 750,000 where the conduct is organized or carried out over a public telecommunications network.

The direct market impact is small. Grand View Research sizes the French nicotine pouch market at USD 10.3 million in 2024, which is roughly 0.3% of the global category by revenue on the same firm's figures. Treat that as one vendor's estimate rather than a measured fact; what is not in doubt is the order of magnitude, which is small. But the significance of this ban has nothing to do with French sales figures. It has everything to do with what happens next across the European Union as the Commission drafts a revision of the tobacco directives and individual member states decide whether prohibition is an acceptable policy tool.

For nicotine ingredient suppliers serving European pouch manufacturers, France is not a revenue event. It is a risk signal.

What France's Ban Actually Covers, and What Is Suspended

One quirk of the decree caused persistent confusion in trade coverage. The text sets entry into force at "the first day of the seventh month following that of its publication." Published in the Journal Officiel on September 6, 2025, that lands on April 1, 2026, not March, which is why some early reporting carried the wrong date.

On December 22, 2025, ruling in emergency proceedings on an application by the manufacturer EVLB, the Conseil d'Etat partially suspended the decree. The suspension is limited to the provisions prohibiting manufacture, production and export. The court reasoned that the timetable did not give the company enough time to reorganize, and noted that sale was already prohibited by other provisions of the Public Health Code. The prohibition on sale, offer, transfer, acquisition and use was expressly left in force.

The merits decision arrived on July 13, 2026, and it did not settle the manufacturing question. Ruling on six joined applications, the Conseil d'Etat was unpersuaded by the challenges to the domestic prohibition on offer, sale, acquisition and use, which it treated as justified on public health grounds. It did not dispose of the cases. Instead it referred a question to the Court of Justice of the European Union: whether Articles 34, 35, 49 and 56 TFEU allow a member state that lawfully bans domestic supply and use to also prohibit production, transport, import, export and possession where those operations are aimed exclusively at marketing the product in another member state. It then stayed every remaining head of claim until the CJEU answers (decision 509446 and joined cases, 13 July 2026).

Read the two halves separately, because they are in different places. The domestic sale ban is in force, and the arguments against it did not persuade the Conseil d'Etat, so nothing about French retail is likely to move soon. The production-for-export question is now before the CJEU, the French cases are stayed behind it, and a reference of this kind commonly takes more than a year to answer. That is the position as we checked it on August 20, 2026. Treat any plan that depends on French production for export as unresolved rather than provisional, and confirm the current status directly before you commit to it.

The manufacturing question is the one worth watching closely, and the referral raised its stakes. If the CJEU answers that a member state may prohibit production for export as well as domestic sale, France will have established a precedent that any member state can use, not merely a French rule. That would be a first, and it would have direct implications for any manufacturer or ingredient supplier with EU production in the chain.

Reaction was not muted. BAT France confirmed compliance. Haypp Group, one of Europe's largest online pouch retailers, ran a deliberately tongue-in-cheek campaign urging customers to boycott French champagne in protest.

The European Regulatory Patchwork: Three Bans and a Spread of Limits

France is not acting in isolation. It joins Belgium, which banned sales in 2023, and the Netherlands, where the sales ban took effect on January 1, 2025.

Beyond outright bans, a second tier of European markets restricts rather than prohibits, which reshapes ingredient demand without eliminating it. These are the rules in force, with the unit each one uses:

Spain's draft deserves attention precisely because it is still a draft. It was notified to the Commission as TRIS 2025/0044/ES on January 24, 2025 and drew detailed opinions from Romania, Czechia, Greece, Italy and Sweden, plus comments from the European Commission and Croatia, largely on free movement of goods grounds. Spain replied in July 2025 and the standstill period has expired, but the Royal Decree has not been adopted. If it ever is in its notified form, a 0.99 mg per pouch ceiling would remove effectively every current product from the Spanish market, which is a far larger demand shock than France's ban.

The pattern for ingredient suppliers tracking global nicotine regulations is clear: EU member states are not waiting for harmonized rules, they are acting unilaterally, and they are not even using the same unit of measure.

The EU Level: Two Files, Neither of Them Finished

Trade coverage tends to blur two separate EU workstreams. They are different instruments, on different legal bases, at different stages, and only one of them concerns product composition at all.

The Product Directive Revision, Often Called TPD3

The current Tobacco Products Directive does not cover tobacco-free nicotine pouches. The Commission's call for evidence says so directly: several novel products, "such as nicotine pouches and heated herbal products, are currently not covered by the Directives."

Closing that gap is a stated objective of the revision, but nothing has been proposed. The Commission published its evaluation of the existing directives on April 2, 2026, ran a call for evidence that closed on June 15, 2026, and closed a twelve-week public consultation on August 14, 2026. The indicative timetable for a legislative initiative is December 2026, and the call for evidence states that all elements, including timing, are subject to change.

The policy options the Commission has named are subject areas, not numbers: extending scope to novel products, rules on flavors, labeling and packaging including plain packaging, and digital marketing. There is no proposed nicotine limit, no proposed flavor list and no proposed packaging specification. The much-quoted 20 mg per gram figure is an analogy to the existing e-liquid ceiling in TPD2, not a Commission position, and our breakdown of what the TPD3 workstream actually contains sets out the documented record.

The Taxation Directive Revision, Which Is Further Along and Currently Stuck

On July 16, 2025 the Commission proposed a revision of the Tobacco Taxation Directive, COM(2025) 580, which would bring nicotine pouches into the harmonized EU excise framework for the first time. Its legal basis is Article 113 TFEU, so the Council must act unanimously with Parliament merely consulted.

That unanimity requirement has bitten. The file stalled in June 2026 without Council agreement, and technical work passed to the Irish presidency on 1 July. The compromise text under discussion has not been published: the figure circulating in trade coverage is a leaked Cypriot presidency draft setting a minimum rate around EUR 95 per kilogram phased in by 2032, down from the EUR 143 per kilogram in the Commission's own proposal. Sweden's objection is the one that matters, because unanimity means one member state is enough. Swedish pouch excise currently sits at SEK 207 per kilogram, and Stockholm has characterised the draft floor as a several-hundred-percent increase that would undermine the smoke-free strategy behind the lowest smoking rate in the EU. Until a Council text is published, treat every rate quoted for this file as provisional.

National excise is not waiting. Austria taxes pouches at EUR 35 per kilogram from April 1, 2026, rising to EUR 40 in 2027 and EUR 45 in 2028. Portugal applies EUR 0.065 per gram from 2026. Finland raised its pouch excise by roughly 37% on January 1, 2026. The cost structure for European pouch manufacturers is changing now, through national law, not through an EU instrument.

France's unilateral ban feeds into both files as political context. Without harmonized rules the patchwork keeps fragmenting, and each national action raises the floor for the next.

Where Ingredient Demand Is Moving

The category is not shrinking. Euromonitor put global nicotine pouch volume at 23.5 billion units in 2024, up from 15.6 billion the year before, a 50.5% increase. The market is reorganizing geographically rather than contracting.

Scandinavia remains the anchor. Sweden benefits from its snus exemption and a settled framework, and sets no concentration limit. Denmark and Finland are tightening but have chosen restriction over prohibition. Ingredient demand from Scandinavian manufacturers continues, though the product mix narrows as flavor rules take hold.

Central and Eastern Europe are the growth edge. Czechia and Hungary regulate by numeric limit rather than prohibition, which keeps their markets open and specifiable. Poland has been debating tighter rules on nicotine pouches without adopting a ban.

The United States remains the single largest market. Euromonitor put US volume at 13.96 billion units in 2024, close to 60% of the global total. While US states are introducing their own regulatory pressures, including excise taxes and flavor bans, no US jurisdiction has imposed an outright ban on nicotine pouches. For ingredient suppliers the US provides a stability baseline no European market currently matches.

The UK is charting its own course. Post-Brexit the UK is outside the EU directives entirely and is developing an independent framework that has generally favored harm reduction over prohibition. Manufacturers serving UK customers face a different compliance landscape from those focused on the EU.

A Risk Assessment Framework for Ingredient Suppliers

Not all European exposure is equal. Evaluate your customer base across four tiers.

Tier 1 (High Risk): Outright Bans. France, Belgium, the Netherlands. No legal domestic market. Ingredient orders for these markets will cease or already have. If you supply manufacturers who were primarily serving them, those orders are gone.

Tier 2 (Elevated Risk): Binding Numeric Limits. Denmark, Latvia, Finland, and Spain if its draft is ever adopted. These markets remain open with narrowing product ranges. Flavor restrictions mean fewer SKUs, and concentration or dose limits change per-unit ingredient volume. Suppliers need flexible nicotine dilution specifications, and the ability to state content in both mg per gram and mg per pouch, because these markets do not use the same unit.

Tier 3 (Moderate Risk): Standard Regulation. Czechia, Hungary, Austria, Luxembourg. Growing markets with manageable but real compliance requirements. Austria in particular now carries a six-month EU-CEG notification lead time and a EUR 3,000 fee per product variant, which raises the cost of a late specification change.

Tier 4 (Lower Risk): Permissive Markets. Sweden, Germany, the UK. Established or stabilizing frameworks and the highest regulatory predictability.

The practical question is what share of your European order volume sits in Tiers 1 and 2. A high concentration there is a diversification problem worth acting on before, not after, the next national measure lands.

What to Do Now: Five Actions for Ingredient Suppliers

1. Map your European customer exposure by country and by unit. Categorize each relationship against the four tiers, and record whether the governing limit is expressed per gram or per pouch. A customer who is compliant in Denmark may be nowhere near compliant in Latvia with the same product.

2. Track the CJEU reference. The question of whether an EU member state can prohibit production for export, and not merely domestic sale, is no longer with the Conseil d'Etat. It went to the Court of Justice on July 13, 2026, and the French cases are stayed until it is answered. Whatever the Court says will apply across the single market, so this now matters to every manufacturer with European production operations, not only to those with French ones.

3. Prepare for specification diversity, not convergence. Binding limits currently sit at 4 mg per gram (Latvia), 9 mg per pouch (Denmark), 12 mg per dose (Czechia), 16.6 mg per gram (Finland) and 17 mg per pouch (Hungary), with Spain's 0.99 mg per pouch draft still live. Suppliers with rigid catalogs will lose business to those who can support multiple concentrations with documentation tailored to each jurisdiction.

4. Strengthen documentation for European notification regimes. Austria requires an EU-CEG filing under section 8d TNRSG six months before market entry. Denmark operates a pre-market registration for oral nicotine products. Both are fed by supplier data. Certificates of analysis, batch traceability records and composition declarations are now market-access documents, not sales collateral.

5. Rebalance toward stable markets. The US carries close to 60% of global volume with no outright ban risk, and Scandinavian markets are growing despite tightening rules. Suppliers who over-indexed on fragmented EU markets should test whether their geographic mix reflects where demand is actually heading.

The European nicotine pouch market is not disappearing. It is being reshaped by a patchwork that rewards suppliers with geographic diversification, flexible specifications, and documentation that travels across jurisdictions. France's fraction of a percent of global revenue is a rounding error. The precedent it sets is not.

NicAlliance supplies USP/EP grade nicotine and nicotine salts with full documentation support, batch traceability, and flexible concentration options for manufacturers navigating evolving regulatory requirements across global markets. If you need a supplier whose documentation meets the compliance bar in every jurisdiction your customers serve, request a sample with full CoA documentation.

Frequently Asked Questions